DaVita Inc
NYSE:DVA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
115.2
177.35
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one
DVA
stock under the Base Case scenario is
265.23
USD.
Compared to the current market price of 117.39 USD,
DaVita Inc
is
Undervalued by 56%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.
Let our AI break down the key assumptions behind the intrinsic value calculation for DaVita Inc.
| US |
|
CVS Health Corp
NYSE:CVS
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
|
| US |
|
Cigna Corp
NYSE:CI
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
|
| US |
|
Guardant Health Inc
NASDAQ:GH
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Heavy reliance on Medicare and Medicaid reimbursement rates significantly exposes DaVita’s profitability to U.S. federal budget changes; any unfavorable regulation or reduced rate hikes could compress margins more than expected.
Acute staffing pressures and labor cost inflation threaten operational efficiency—DaVita’s specialized workforce requirements may drive operational disruptions or limit the company’s ability to expand dialysis centers profitably.
Expanding competition from smaller clinic networks and hospital-based providers could challenge DaVita’s market share, especially if payers direct patients toward lower-cost or integrated care models.
DaVita’s large-scale network of outpatient dialysis centers creates barriers to entry, giving the company significant negotiating power with suppliers and payers and helping stabilize its profitability in the long run.
The ongoing shift toward value-based care and integrated kidney care provides DaVita an opportunity to leverage its care coordination capabilities, potentially generating higher patient retention and incremental revenue streams.
Strong recurring revenue from chronic dialysis treatments, combined with a stable end-stage renal disease patient base, underpins DaVita’s predictable cash flows and supports strategic reinvestments in technology and care innovation.
Revenue & Expenses Breakdown
DaVita Inc
Balance Sheet Decomposition
DaVita Inc
| Current Assets | 4.1B |
| Cash & Short-Term Investments | 736.5m |
| Receivables | 3B |
| Other Current Assets | 389.5m |
| Non-Current Assets | 13.4B |
| Long-Term Investments | 299.6m |
| PP&E | 5.2B |
| Intangibles | 7.8B |
| Other Non-Current Assets | 204.5m |
| Current Liabilities | 3B |
| Accounts Payable | 655.6m |
| Accrued Liabilities | 1.3B |
| Other Current Liabilities | 1.1B |
| Non-Current Liabilities | 15.1B |
| Long-Term Debt | 10.2B |
| Other Non-Current Liabilities | 4.9B |
Free Cash Flow Analysis
DaVita Inc
| USD | |
| Free Cash Flow | USD |
Earnings Waterfall
DaVita Inc
|
Revenue
|
13.3B
USD
|
|
Cost of Revenue
|
-9.1B
USD
|
|
Gross Profit
|
4.3B
USD
|
|
Operating Expenses
|
-2.3B
USD
|
|
Operating Income
|
1.9B
USD
|
|
Other Expenses
|
-1.2B
USD
|
|
Net Income
|
771.9m
USD
|
DVA Profitability Score
Profitability Due Diligence
DaVita Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
Score
DaVita Inc's profitability score is 50/100. The higher the profitability score, the more profitable the company is.
DVA Solvency Score
Solvency Due Diligence
DaVita Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
DaVita Inc's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
DVA Price Targets Summary
DaVita Inc
According to Wall Street analysts, the average 1-year price target for
DVA
is 141.36 USD
with a low forecast of 127.26 USD and a high forecast of 157.5 USD.
Dividends
Current shareholder yield for
DVA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
DVA
stock under the Base Case scenario is
265.23
USD.
Compared to the current market price of 117.39 USD,
DaVita Inc
is
Undervalued by 56%.